There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avita Medical (RCEL – Research Report) and CVRx (CVRX – Research Report) with bullish sentiments.
Avita Medical (RCEL)
Lake Street analyst Brooks O’Neil maintained a Buy rating on Avita Medical today and set a price target of $40.00. The company’s shares closed last Tuesday at $8.98, close to its 52-week low of $8.46.
According to TipRanks.com, O’Neil is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avita Medical with a $26.40 average price target, representing a 208.4% upside. In a report issued on April 11, Piper Sandler also maintained a Buy rating on the stock with a $21.00 price target.
See today’s best-performing stocks on TipRanks >>
CVRx (CVRX)
In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on CVRx, with a price target of $35.00. The company’s shares closed last Tuesday at $14.29.
According to TipRanks.com, Takkinen is a 3-star analyst with an average return of
Currently, the analyst consensus on CVRx is a Strong Buy with an average price target of $34.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RCEL:
- AVITA Medical to Announce First Quarter 2024 Financial Results
- Avita Medical downgraded to Neutral from Buy at BTIG
- AVITA Medical Updates Expected First Quarter 2024 Revenue
- Avita Medical backs FY24 revenue view $78.5M-$84.5M, consensus $80.09M
- Avita Medical cuts Q1 commercial revenue view to $11M-$11.3M from $14.8M-$15.6M
